Kirsty Bannister

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3852916/publications.pdf

Version: 2024-02-01

46 papers	1,963 citations	236925 25 h-index	265206 42 g-index
49 all docs	49 docs citations	49 times ranked	2138 citing authors

#	Article	IF	Citations
1	One size does not fit all: towards optimising the therapeutic potential of endogenous pain modulatory systems. Pain, 2023, 164, e5-e9.	4.2	6
2	Distinct brainstem to spinal cord noradrenergic pathways inversely regulate spinal neuronal activity. Brain, 2022, 145, 2293-2300.	7.6	16
3	Irritable bowel syndrome in inflammatory bowel disease: Distinct, intertwined, or unhelpful? Views and experiences of patients. Cogent Psychology, 2022, 9, .	1.3	4
4	Opicapone versus placebo in the treatment of Parkinsonâ€™s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.8	8
5	The impact of paradigm and stringent analysis parameters on measuring a net conditioned pain modulation effect: A test, retest, control study. European Journal of Pain, 2021, 25, 415-429.	2.8	13
6	Challenges and opportunities in translational pain research â€“ An opinion paper of the working group on translational pain research of the European pain federation (EFIC). European Journal of Pain, 2021, 25, 731-756.	2.8	28
7	European* clinical practice recommendations on opioids for chronic noncancer pain â€“ Part 1: Role of opioids in the management of chronic noncancer pain. European Journal of Pain, 2021, 25, 949-968.	2.8	55
8	Towards optimising experimental quantification of persistent pain in Parkinsonâ€™s disease using psychophysical testing. Npj Parkinson's Disease, 2021, 7, 28.	5.3	11
9	Pain in Parkinson's disease: Mechanism-based treatment strategies. Current Opinion in Supportive and Palliative Care, 2021, 15, 108-115.	1.3	11
10	European clinical practice recommendations on opioids for chronic noncancer pain â€“ Part 2: Special situations*. European Journal of Pain, 2021, 25, 969-985.	2.8	17
11	Developments in Understanding Diffuse Noxious Inhibitory Controls: Pharmacological Evidence from Pre-Clinical Research. Journal of Pain Research, 2021, Volume 14, 1083-1095.	2.0	10
12	Assessment of Somatosensory Function and Self-harm in Adolescents. JAMA Network Open, 2021, 4, e2116853.	5.9	9
13	Introducing descending control of nociception: a measure of diffuse noxious inhibitory controls in conscious animals. Pain, 2021, 162, 1957-1959.	4.2	17
14	Editorial: Plasticity of Endogenous Pain Modulatory Circuits in Neuropathy. Frontiers in Pain Research, 2021, 2, 776948.	2.0	0
15	Neuropathic Pain: Mechanism-Based Therapeutics. Annual Review of Pharmacology and Toxicology, 2020, 60, 257-274.	9.4	129
16	Selective modulation of tonic aversive qualities of neuropathic pain by morphine in the central nucleus of the amygdala requires endogenous opioid signaling in the anterior cingulate cortex. Pain, 2020, 161, 609-618.	4.2	34
17	The Stage-Specific Plasticity of Descending Modulatory Controls in a Rodent Model of Cancer-Induced Bone Pain. Cancers, 2020, 12, 3286.	3.7	9
18	Central Nervous System Targets: Supraspinal Mechanisms of Analgesia. Neurotherapeutics, 2020, 17, 839-845.	4.4	15

#	Article	IF	Citations
19	The impact of bone cancer on the peripheral encoding of mechanical pressure stimuli. Pain, 2020, 161, 1894-1905.	4.2	13
20	Activation of the descending pain modulatory system using cuff pressure algometry: Back translation from man to rat. European Journal of Pain, 2020, 24, 1330-1338.	2.8	29
21	Supraspinal Opioid Circuits Differentially Modulate Spinal Neuronal Responses in Neuropathic Rats. Anesthesiology, 2020, 132, 881-894.	2.5	10
22	Descending pain modulation: influence and impact. Current Opinion in Physiology, 2019, 11, 62-66.	1.8	19
23	Kappa opioid signaling in the right central amygdala causes hind paw specific loss of diffuse noxious inhibitory controls in experimental neuropathic pain. Pain, 2019, 160, 1614-1621.	4.2	45
24	An investigation into the noradrenergic and serotonergic contributions of diffuse noxious inhibitory controls in a monoiodoacetate model of osteoarthritis. Journal of Neurophysiology, 2019, 121, 96-104.	1.8	44
25	Editorial for Pain: Nonmalignant Diseases in 2018. Current Opinion in Supportive and Palliative Care, 2018, 12, 131.	1.3	0
26	Morphine effects within the rodent anterior cingulate cortex and rostral ventromedial medulla reveal separable modulation of affective and sensory qualities of acute or chronic pain. Pain, 2018, 159, 2512-2521.	4.2	46
27	An investigation into the inhibitory function of serotonin in diffuse noxious inhibitory controls in the neuropathic rat. European Journal of Pain, 2017, 21, 750-760.	2.8	54
28	Hopes for the Future of Pain Control. Pain and Therapy, 2017, 6, 117-128.	3.2	42
29	The plasticity of descending controls in pain: translational probing. Journal of Physiology, 2017, 595, 4159-4166.	2.9	110
30	Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. Pain, 2017, 158, 2386-2395.	4.2	74
31	Effect of the spider toxin Tx3-3 on spinal processing of sensory information in naive and neuropathic rats: an in vivo electrophysiological study. Pain Reports, 2017, 2, e610.	2.7	11
32	What the brain tells the spinal cord. Pain, 2016, 157, 2148-2151.	4.2	41
33	What do monoamines do in pain modulation?. Current Opinion in Supportive and Palliative Care, 2016, 10, 143-148.	1.3	92
34	Diffuse noxious inhibitory controls and nerve injury. Pain, 2015, 156, 1803-1811.	4.2	137
35	Opioid-induced hyperalgesia. Current Opinion in Supportive and Palliative Care, 2015, 9, 116-121.	1.3	37
36	Circuitry and plasticity of the dorsal horn â€" Toward a better understanding of neuropathic pain. Neuroscience, 2015, 300, 254-275.	2.3	88

#	Article	IF	Citations
37	Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. Brain, 2015, 138, 28-35.	7.6	120
38	Cancer pain physiology. British Journal of Pain, 2014, 8, 154-162.	1.5	36
39	Neuropathic plasticity in the opioid and non-opioid actions of dynorphin A fragments and their interactions with bradykinin B2 receptors on neuronal activity in the rat spinal cord. Neuropharmacology, 2014, 85, 375-383.	4.1	27
40	Brainstem facilitations and descending serotonergic controls contribute to visceral nociception but not pregabalin analgesia in rats. Neuroscience Letters, 2012, 519, 31-36.	2.1	27
41	Mu-opioid and noradrenergic Î±2-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain, 2011, 152, 131-139.	4.2	72
42	A pronociceptive role for the 5-HT2 receptor on spinal nociceptive transmission: An in vivo electrophysiological study in the rat. Brain Research, 2011, 1382, 29-36.	2.2	42
43	Pregabalin Suppresses Spinal Neuronal Hyperexcitability and Visceral Hypersensitivity in the Absence of Peripheral Pathophysiology. Anesthesiology, 2011, 115, 144-152.	2.5	50
44	Opioid hyperalgesia. Current Opinion in Supportive and Palliative Care, 2010, 4, 1-5.	1.3	56
45	Preclinical and Early Clinical Investigations Related to Monoaminergic Pain Modulation. Neurotherapeutics, 2009, 6, 703-712.	4.4	132
46	Descending Serotonergic Facilitation and the Antinociceptive Effects of Pregabalin in a Rat Model of Osteoarthritic Pain. Molecular Pain, 2009, 5, 1744-8069-5-45.	2.1	116